en · de · es · fr · pt
peptide-index.peptides9002.com › Wiki › Identity And Structural Background — Deep Dive

Identity And Structural Background — Deep Dive

By Editorial Desk · published 2026-07-11 · last reviewed 2026-08-01 · Wiki

This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Identity and Structural Background

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Stability, Handling, and Analytical Control

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.

Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.

Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideTuftsin analogue
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProSingle-letter form: TKPRPGP
Molecular formulaC33H57N11O9Calculated for the free peptide
Molecular weightAbout 751.9 g/molDerived from the sequence
AppearanceWhite to off-white powderTypical lyophilised form

Mechanism and Evidence Status

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Related pages on this site

Analytical Methods And Storage Stability

Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.

Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.

Peptide Identity and Structure

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Supporting material

Under the Treaty on the Functioning of the European Union article 56 there is the right to receive services, with rules codified into the Patients' Rights Directive 2011. Article 4 requires that people are treated, article 5 requires reimbursement of costs by the person's country of origin, article 6 requires national contact points to connect healthcare providers or insurers and patient organisations, but under article 8 member states may require prior authorisation for people to travel abroad for treatment where the costs are high or planning is needed. A European Health Insurance Card is also available for free to receive health across the EU. This system was developed after R (Watts) v Bedford Primary Care Trust, where in 2003 Mrs Watts travelled from the UK to France, paid £3900 for a hip replacement operation, and claimed she should be reimbursed. The UK's National Health Service waiting lists were 4 to 6 months at the time. The Court of Justice's Grand Chamber held that health care counted as a 'service' under TFEU article 56, and that in principle there was a right to receive those services abroad. However, high demand could justify waiting lists in a national health system, but individual circumstances of the patient had to be assessed. For non-EU nationals, the European Court of Human Rights held in N v United Kingdom that it was not inhuman and degrading treatment contrary to ECHR article 3 to deport someone to a country where there were unlikely to live longer than two years without treatment.

== Occurrence and causes == Chronic kidney disease is one of the most common causes of death in older domestic cats. In many animals, however, the disease initially remains unrecognized, as clinical symptoms are often absent in the early stages of chronic kidney disease due to the kidney's reserve capacity and sufficiently sensitive diagnostic tests are not available for routine use. The data on the frequency of the disease in cats is contradictory, varying between 1.6 and 20%. Chronic kidney disease occurs more frequently in older cats: Over 50% of affected cats are seven years old or older and 30% of all cats over 9 years of age show elevated blood levels of nitrogen compounds (azotemia). However, the disease can occur as early as 9 months of age. Disposition predisposition has been proven for Maine Coon, Abyssinian, Siamese, Russian Blue and Burmese. Since the kidneys have a high reserve capacity and clinical symptoms only appear when two thirds of the original kidney function has been lost, the triggering factors must damage both kidneys. Chronic kidney disease in cats is an idiopathic tubulointerstitial nephritis, i.e. an inflammation of the renal tubules and the renal interstitial tissue without an identifiable cause. In addition to the damage that this primary disease causes directly to the kidney tissue, activated endogenous repair mechanisms such as connective tissue formation lead to further, partially self-sustaining destruction of functional kidney tissue.

The Kizil Caves (also romanized as Qizil or Qyzyl; Uyghur: قىزىل مىڭ ئۆي, lit. 'The Thousand Red Houses'; Chinese: 克孜尔千佛洞; lit. 'Kizil Caves of the Thousand Buddhas') are a set of Buddhist rock-cut caves located near Kizil Township (克孜尔乡; Kèzī'ěr Xiāng) in Baicheng County, Aksu Prefecture, Xinjiang, China. The site is located on the northern bank of the Muzat River 65 kilometres (40 miles) (75 km; 50 miles by road) west of Kucha. This area was a commercial hub of the Silk Road. The caves have an important role in Central Asian art and in the Silk Road transmission of Buddhism, and are said to be the earliest major Buddhist cave complex in China, with development occurring between the 3rd and 8th centuries CE. The caves of Kizil are the earlier of their type in China, and their model was later adopted in the construction of Buddhist caves further east. Another name for the site has been Ming-oi (明屋), although this term is now mainly used for the site of Shorchuk to the east. The Kizil Caves were inscribed in 2014 on the UNESCO World Heritage List as part of the Silk Roads: the Routes Network of Chang'an-Tianshan Corridor World Heritage Site.

The PAH world hypothesis is a speculative hypothesis that proposes that polycyclic aromatic hydrocarbons (PAHs), known to be abundant in the universe, including in comets, and assumed to be abundant in the primordial soup of the early Earth, played a major role in the origin of life by mediating the synthesis of RNA molecules, leading into the RNA world. However, as yet, the hypothesis is untested.

Pu-239 is produced artificially in nuclear reactors when a neutron is absorbed by U-238, forming U-239, which then decays in a rapid two-step process into Pu-239. It can then be separated from the uranium in a nuclear reprocessing plant. Weapons-grade plutonium is defined as being predominantly Pu-239, typically about 93% Pu-239. Pu-240 is produced when Pu-239 absorbs an additional neutron and fails to fission. Pu-240 and Pu-239 are not separated by reprocessing. Pu-240 has a high rate of spontaneous fission, which can cause a nuclear weapon to pre-detonate, producing a fizzle. This makes plutonium unsuitable for use in gun-type nuclear weapons. To reduce the concentration of Pu-240 in the plutonium produced, weapons program plutonium production reactors (e.g. B Reactor) irradiate the uranium for a far shorter time than is normal for a nuclear power reactor. More precisely, weapons-grade plutonium is obtained from uranium irradiated to a low burnup. This represents a fundamental difference between these two types of reactor. In a nuclear power station, high burnup is desirable. Power stations such as the obsolete British Magnox and French UNGG reactors, which were designed to produce either electricity or weapons material, were operated at low power levels with frequent fuel changes using online refuelling to produce weapons-grade plutonium. Such operation is not possible with the light water reactors most commonly used to produce electric power. In these the reactor must be shut down and the pressure vessel disassembled to gain access to the irradiated fuel.

Sources: en.wikipedia.org

Notes from published material

Albumin I (PA1b) is a hormone-like peptide found in the seeds of legumes such as the pea plant (Pisum sativum) or soya bean (Glycine max) which have been shown to have insecticidal properties. It stimulates kinase activity upon binding a membrane bound 43 kDa receptor within the plant which affects cell proliferation. The structure reveals an inhibitor cystine knot (knottin)-like fold, comprising three beta strands.

=== Jason: The Pretty-Boy Bully === First aired 3 September 2009 Jason gets in the ring with MMA fighter Jon Murphy. Out of the $5,000 he could have won in the first round, Jason walked away with $2,000, and in the kick boxing round lost and the Victims got the $5,000. After giving Jason a wedgie, Mayhem refers to the bully beatdown as 'God's Work'. Victims- Step Brother, and friend from High school

== Efficacy == There is currently no standardized form of dry needling. There is a general scarcity of extensive research in the field. Many studies published about dry needling are not randomized, contain small sample sizes, and have high dropout rates. A review recommended the usage of dry needling, compared to sham or placebo, for decreasing pain immediately after treatment and at 4 weeks in patients with upper quarter myofascial pain syndrome. However, the authors caution that "the limited number of studies performed to date, combined with methodological flaws in many of the studies, prompts caution in interpreting the results of the meta-analysis performed". Similarly, a second review of dry needling found insufficient high-quality evidence for the use of direct dry needling for short and long-term pain and disability reduction in patients with musculoskeletal pain syndromes. The same review reported that robust evidence validating the clinical diagnostic criteria for trigger point identification or diagnosis is lacking and that high-quality studies demonstrate that manual examination for the identification and localization of a trigger point is neither valid nor reliable between examiners.

=== Pregnancy === Dexamethasone may be given to women at risk of delivering prematurely to promote maturation of the fetus's lungs. This administration, given from one day to one week before delivery, has been associated with low birth weight, although not with increased rates of neonatal death. Dexamethasone has also been used during pregnancy as an off-label prenatal treatment for the symptoms of congenital adrenal hyperplasia (CAH) in female babies. CAH causes a variety of physical abnormalities, notably ambiguous genitalia. Early prenatal CAH treatment has been shown to reduce some CAH symptoms, but it does not treat the underlying congenital disorder. This use is controversial: it is inadequately studied, only around one in ten of the fetuses of women treated are at risk of the condition, and serious adverse events have been documented. Experimental use of dexamethasone in pregnancy for fetal CAH treatment was discontinued in Sweden when one in five cases had adverse events. A small clinical trial found long-term effects on verbal working memory among the small group of children treated prenatally, but the small number of test subjects means the study cannot be considered definitive.

Sources: en.wikipedia.org

Background from the literature

Medical laboratory assistants (MLAs) also known as clinical laboratory assistants (CLA) or clinical assistants (CA) prepare, and in some cases process samples within a pathology laboratory. They also utilise pre-analytical systems in order for biomedical scientists (BMS) or Medical Laboratory Scientific Officers to process the biochemical tests requested on the sample. The majority of an MLA's time is spent in processing specimens. As such, the MLA has to have excellent knowledge of their particular sample acceptance policy, whilst obeying the data protection act, patient confidentiality, COSHH and the Caldicott rules. Other duties an MLA may undertake include, setting up blood analyzers, running Quality Controls and manual controls prior to a BMS undertaking analysis on samples. Maintenance and decontamination is essential for the function of the machinery therefore MLAs carry out this role on a weekly or monthly basis. A typical method of sample acceptance (in a clinical chemistry lab) is as follows:

Bio-Synthesis, Inc. (BSI) is a biotechnology company headquartered in Lewisville, Texas. It is a provider of custom and catalog peptides, custom oligos, antibodies, organic synthesis, and analytical services. Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project.

=== Headache === Amitriptyline is probably effective for the prevention of periodic migraine in adults. Amitriptyline is similar in efficacy to venlafaxine and topiramate but carries a higher burden of adverse effects than topiramate. For many patients, even small doses of amitriptyline are helpful, which may allow for minimization of side effects. Amitriptyline is not significantly different from placebo when used for the prevention of migraine in children. Amitriptyline may reduce the frequency and duration of chronic tension headache, but it is associated with worse adverse effects than mirtazapine. Overall, amitriptyline is recommended for tension headache prophylaxis, along with lifestyle advice, which should include avoidance of analgesia and caffeine.

Sources: en.wikipedia.org

Frequently asked questions

What is the peptide sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.

How is it related to tuftsin?

Selank is a synthetic analogue built on the tuftsin tetrapeptide Thr-Lys-Pro-Arg. Extra proline residues were added to the C-terminus during design work. That modification is intended to make the peptide less vulnerable to rapid enzymatic degradation.

Why do different sources use different names?

Transliteration from Russian produces variant spellings such as Selanc. Many suppliers avoid the trade-style name entirely and list the peptide sequence. Comparing sequences rather than names is the reliable way to confirm two entries describe the same molecule.

How should the powder be stored?

Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.

Network